Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Pharmacokinetics of CamSA, a potential prophylactic compound against Clostridioides difficile infections

Biochemical Pharmacology(2020)10.1016/j.bcp.2020.114314Source: DataRank Database

Pharmacokinetics of CamSA, a potential prophylactic compound against Clostridioides difficile infections is a research paper published in Biochemical Pharmacology (2020). On theSindex it has a DataRank of 0. It has been cited 17 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access17 citations

Download PDF

Cite:

Linked data & code

doi

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (5 grants)Impact (FWCI 0.24)OA: greenTopics (48)IDs (PubMed, PMC, OpenAlex)Annotations (1)SDGs (2)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (5)

Naomi C. Okada ORCID,Amber Howerton,Amei Amei ORCID,Ernesto Abel‐Santos ORCID,Christopher Yip ORCID

Live enrichment

PubMed:33152344 PMC:PMC7770080 OpenAlex:https://openalex.org/W3097539453

NCRR NIH HHS

Grant: P20 RR016464

NIAID NIH HHS

Grant: R01 AI109139

NIAID NIH HHS

Grant: R15 AI103883

National Institutes of Health

Grant: 5R01AI109139-05

Prophylaxis of Clostridium difficile infection

National Institute of Allergy and Infectious Diseases

FWCI

0.24

Citation Percentile

0.7%

Citation Trend

2021

2022

2023

2025

2026

greenLicense: Elsevier TDM

repositoryhttps://www.ncbi.nlm.nih.gov/pmc/articles/7770080

publisherhttps://api.elsevier.com/content/article/PII:S0006295220305505?httpAccept=text/xml

publisherhttps://api.elsevier.com/content/article/PII:S0006295220305505?httpAccept=text/plain

journalhttps://doi.org/10.1016/j.bcp.2020.114314

Fields of Study

Clostridium difficile and Clostridium perfringens researchPharmacological Effects of Natural CompoundsHelicobacter pylori-related gastroenterology studies0301 basic medicine0303 health sciences03 medical and health sciences

MeSH Terms

Gastrointestinal MicrobiomeAnimalsBile Acids and SaltsClostridium InfectionsFecesFemaleMice, Inbred C57BLClostridioides difficileMicePre-Exposure Prophylaxis

Keywords

PharmacokineticsEnterohepatic circulationAntibioticsGastrointestinal tractSpore germinationMicrobiologyPharmacologyCYP3A4BiologyIn vivoDrug metabolismSporeMetabolismDrugCytochrome P450BiochemistryLiverIntestineCDIDrug therapyBile saltsMicrobiomeClostridioides DifficileGastrointestinal MicrobiomeBile Acids and SaltsMice, Inbred C57BLFecesMiceClostridium InfectionsAnimalsFemalePre-Exposure Prophylaxis

Sustainable Development Goals

SDG 3: 3. Good healthSDG 0: Good health and well-being

Pharmacokinetics of CamSA, a potential prophylactic compound against Clostridioides difficile infections

FAIR Checklist

Authors (5)

Funding (5 grants)

Impact

Open Access

Topics

Annotations (Europe PMC)